Horizon Pharma plc Announces Collaboration With Alliance for Lupus Research to Study RAYOS(R) (prednisone) Delayed-Release Tablets in Systemic Lupus Erythematosus

Go back to Horizon Pharma plc Announces Collaboration With Alliance for Lupus Research to Study RAYOS(R) (prednisone) Delayed-Release Tablets in Systemic Lupus Erythematosus

Linden Disruption Expected to Have 'Minimal Impact' on Horizon Pharma (HZNP) - Mizuho

November 11, 2015 11:57 AM EST

Mizuho Securities analyst Irina Koffler reiterated a Buy rating and $34 price target on Horizon Pharma (NASDAQ: HZNP), saying they expect minimal impact from Linden disruption.

Koffler commented, "We spoke with management and learned that Linden processes ~150-200 prescriptions for Duexis, Vimovo, Pennsaid, and... More

Horizon Pharma (HZNP) Enteres Collaboration with ALR for RAYOS Study in SLE

November 11, 2015 7:05 AM EST

Horizon Pharma (NASDAQ: HZNP) announced a collaboration with the Alliance for Lupus Research (ALR) to study RAYOS (prednisone) delayed-release tablets in systemic lupus erythematosus (SLE), a chronic autoimmune disease that causes inflammation and pain in the joints and muscles as well as overall fatigue.

"Despite advances in SLE therapies, sustained control of disease activity is limited to a small fraction of patients," said Jeffrey D. Kent, M.D., FACG, senior vice president, medical affairs and outcomes research, Horizon Pharma plc. "Prednisone is the steroid most commonly prescribed for lupus and given the unique... More